# Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

> **NCT03475004** · PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 53 (actual)

## Conditions studied

- Colorectal Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Bevacizumab
- **DRUG:** Binimetinib

## Key facts

- **NCT ID:** NCT03475004
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-17
- **Primary completion:** 2022-04-14
- **Final completion:** 2024-02-12
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03475004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03475004, "Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03475004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*